Midregional proadrenomedullin plasma concentration in emergency patients with dyspnea due to respiratory disease: A pilot study;Estudio piloto de la utilidad de la región medial de la proadrenomedulina (RM-proADM) en la valoración de la disnea de origen respiratorio en urgencias

Emergencias

Volumn 24, Issue 5, 2012, Pages 357-365

  Herrero Puente, Pablo ^a   Fernández García, Daniel ^a   Gil Roḿn, Jose Juan ^a   Prieto García, Belén ^a   Vázquez Álvarez, Joaquín ^a   Miguel Fernández, Diego ^a   Houghton, Richard ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Adrenomedullin; Dyspnea; Emergency health services

Indexed keywords

EID: 84867408946     PISSN: 11376821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin, a novel hypotensive peptide isolated from human phaeocromocitom. Biochem Biophys Res Comm. 1993;192:553-60.
2. Asada Y, Hara S, Marutsuka K, Kitamura K, Tsuji T, Sakata J, et al. Novel distribution of adrenomedullin-inmunorreactive cells in human tissues. Histochem Cell Biol. 1999;112:185-91.
3. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000;21:138-67.
4. Kato J, Kitamura K, Matsui E, Tanaka M, Ishizaka Y, Kita T, et al. Plasma adrenomedullin and natriuretic peptides in patients with essential and malignant hypertension. Hypertens Res. 1999;22:61-5.
5. Kobayashi K, Kitamura K, Hirayama N, Date H, Kashiwagi T, Ikushima I, et al. Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J. 1996;131:676-80.
6. Jougasaki M, Wei CM, McKinley LJ, Burnet JC. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation. 1995;92:286-9.
7. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrolol. 2009;5:677-89.
8. Turk HM, Buyukberber S, Sevine A, Ak G, Ates M, Sari R, et al. Relationship between plasma adrenomedullin levels and metabolic control, risk factors and diabetic microangiopathy in patients with type 2 diabetes. Diabetes Care. 2000;23:864-7.
9. Ehlenz K, Koch B, Preuss P, Simon B, Koop I, Lang RE. High levels of circulating adrenomedullin in severe illness: correlation with C-reactive protein and evidence against the adrenal medulla as site of origin. Exp Clin Endocrinol Diabetes. 1997;105:156-62.
10. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patioents. Peptides. 2004;25:1369-72.
11. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005;51:1823-9
12. Flores CR. La saturación de los servicios de urgencias: una llamada a la unidad. Emergencias. 2011;23:59-64.
13. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care. 2005;9:R816-824.
14. Christ-Crain M, Morgenthaler NG, Stolz D, Müller C, Bingisser R, Harbarth S. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit Care. 2006;10:R96.
15. Huang DT, Kellum JA, Struck J, Rosengart MR. Midregional Proadrenomedullin as a Prognostic Tool in Community-Acquired Pneumonia. Chest. 2009;136:823-31.
16. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.
17. Potocki M, Breidhardt T, Reichlin T, Morgenthaler NG, Bergmann A, Noveanu M, et al. Midregional pro-Adrenomedullin in adition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an obervational study. Crit Care. 2009;13:R122.
18. Maisel A, Mueller C, Nowak R, Peacock F, Landsberg JW, Ponikowski P. Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea. Results from the BACH (Biomarkers in Acute Heart Failure) Trial. J Am Coll Cardiol. 2010;55:2062-76.
19. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1974;285:1441-6.
20. Grupo español de Triaje de Manchester. (Consultado 31 Julio 2011). Disponible en URL: www.triajemanchester.com
21. Stolz D, Christ-Crain M, Morgenthaler NG, Miedinger D, Leuppi J, Müller C, et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest. 2008;134:263-72.
22. Van del Wulp I, Schrijvers AJ, Van Stel HF. Predicting admission and mortality with the Emergency Severity Index and the Manchester Triage System: a retrospective observational study. Emerg Med J. 2009;26:506-9.
23. Smith JG, Newton-Cheh C, Hedblad B, Struck J, Morgenthaler NG, Bergmann A, et al. Distribution and Correlates of Midregional Proadrenomedullin in the General Population. Clin Chem. 2009;55:1593-5.
24. Llorens P, Murcia J, Laghazaoui F, Martínez-Beloqui E, Pastor R, Marquina V, et al. Estudio epidemiológico de la neumonía adquirida en la comunidad diagnosticada en un servicio de urgencias: ¿influye el índice de Fine en la toma de decisiones? Emergencias. 2009;21:247-54.
25. Chua M, Hoyle GE, Soiza RL. Prognostic implications of hyponatremia in elderly hospitalized patients. Arch Gerontol Geritr. 2007;45:253-8.
26. Julián Jiménez A, Palomo de los Reyes MJ, Ortiz Díaz-Miguel R, Pedroso Guerrero A, Parejo Míguez R, Salcedo Martínez R. Utilidad de la procalcitonina y la proteína C reactiva en el paciente con sepsis en urgencias. Emergencias. 2009;21:23-7.
27. Cabré M, Serra-Prat M, Force Ll, Palomera E, Pallarés R. Funcional status as a risk factor for mortality in very elderly patients with pneumonia. Med Clin (Barc). 2008;131:167-70.